Investor search results
417 investors found
🌍 United States🏷 Clinical Trials
Popular searches
Tom V.
Founder-Principal at Esalen Ventures, guiding startups to success in venture capital.
87
investments
Mohamed (Sid) Siddeek
Corporate Vice President and Head of NVentures, NVIDIA’s Venture Capital Group
76
investments
Caroline Farah Lembck, MBA, PhD (abd)
American Businesswoman, Investor & Entrepreneur Founder of LemVega Capital®, Puerto Rico’s leading investment firm going global | Featured NasDaq, Forbes | BA at 19 years old | MBA at 20 | PhD started at 20 | CEO at 21
76
investments
…
Frequently asked questions about Clinical Trials investors in United States
How many Clinical Trials investors are there in United States?
Gritt tracks 413 Clinical Trials investors in United States, of which 251 (61%) have a direct email address available.
How can I contact Clinical Trials investors in United States?
Gritt provides direct email addresses for 61% of investors in this list. Once you have an account, you can export the list or use Gritt AI outreach to draft personalised emails that you review and approve, then send from your Gmail.
Are these investors actively investing in United States startups?
Yes — Gritt ranks investors by their investment activity. The investors at the top of this list have made the most investments in Clinical Trials companies and are most likely to be actively seeking new deals.
Can I filter by investment stage or industry?
Yes — use the filters on the left to narrow by investment stage (early, mid, late) or industry. You can also filter by last active date to focus on investors who have made deals recently.
Can I export this list of Clinical Trials investors in United States?
Yes — paid Gritt accounts can export any filtered investor list as a CSV, including names, email addresses, LinkedIn profiles and investment counts.
Contact all 413 Clinical Trials investors
Gritt drafts a personalised AI email for each — written from your pitch; you approve each one, then it sends from your Gmail.
Start free — contact these investors